The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Friends study points to ctDNA’s potential to serve as an intermediate endpoint in NSCLC
ctMoniTR project aims to improve efficiency in development of intermediate endpoints

Cancer Policy

Shutdown precluded NCI officials from appearing at AACI/CCAF annual meeting

Science advocates organize march in DC to demand impeachment of RFK Jr.

Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA

Federal official claims that temporary order blocking RIFs doesn’t apply to HHS

Insurance premiums set to skyrocket if Congress doesn’t reach a deal

Trump cuts IVF drug deal with Merck in exchange for tariff exemption

Clinical Roundup

Zanzalintinib + atezolizumab improve survival in advanced CRC

Trodelvy reduces risk of disease progression or death by 38% vs. chemo as first-line therapy in metastatic TNBC

Enhertu reduced the risk of disease recurrence or death vs. T-DM1 in high-risk HER2+ early breast cancer following neoadjuvant therapy

Enhertu + THP before surgery resulted in a pathologic complete response in high-risk HER2+ early-stage breast cancer

Keytruda shows long-term survival benefit in NSCLC

Keytruda + Padcev reduced risk of EFS events and death for muscle-invasive bladder cancer when given before and after surgery

In The Clinic
Regulatory NewsTrials & Tribulations

Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research

Trials & Tribulations
Conversation with The Cancer Letter
Trials & Tribulations

The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account